Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06671379 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC

StatusActive, Not Recruiting
PhasePhase 3
Started2024-11-29
View on ClinicalTrials.gov ↗

Amendment history

2026-03-18
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v2
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 500→confirmed 498
Study sitesdetails revised at 1 of 1 site
2024-12-30
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-11→confirmed 2024-11-29
Study sites0→1
2024-11-01
Original filing
This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or metastatic non-small cell lung cancer who failed EGFR TKI treatment.
Trial Details
NCT Number NCT06671379
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Non-small Cell Lung Cancer
Enrollment 498 participants
Start Date 2024-11-29
Primary Completion 2026-12 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-19